Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
The low EOMES/TBX21 molecular phenotype in multiple sclerosis reflects CD56+ cell dysregulation and is affected by immunomodulatory therapies.
Glatiramer acetate ameliorates inflammatory bowel disease in mice through the induction of Qa-1-restricted CD8⁺ regulatory cells.
Impact of cladribine on soluble adhesion molecules in multiple sclerosis.
Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis.
Prevalence of neurological disorders in Al Quseir, Egypt: methodological aspects.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Focal vibration in neurorehabilitation.
Interferon-β-1b: a review of its use in multiple sclerosis.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Santhera's Phase III program with Catena®/Raxone® in Duchenne muscular dystrophy on track to deliver pivotal data early in 2Q 2014
Genzyme’s LEMTRADA™ (alemtuzumab) application for MS accepted for review by the FDA
Quantifying brain volumes for Multiple Sclerosis patients follow-up in clinical practice - comparison of 1.5 and 3 Tesla magnetic resonance imaging.
Attenuation of 7-ketocholesterol-induced overproduction of reactive oxygen species, apoptosis, and autophagy by dimethyl fumarate on 158N murine oligodendrocytes.
Clinically feasible MTR is sensitive to cortical demyelination in MS.
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Heterogeneity of serum gelatinases MMP-2 and MMP-9 isoforms and charge variants.
Neuroprotection with glatiramer acetate: evidence from the PreCISe trial.
Relationship between NMO-antibody and anti-MOG antibody in optic neuritis.
Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis.

Pages